Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous daily sunitinib for recurrent glioblastoma

(2012) Teri Nguyen Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

(2011) Evan J. Wuthrick et al.   CANCER

Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review

(2011) Pieter L Kubben et al.   LANCET ONCOLOGY

Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery

(2011) A. Castellano et al.   NEURO-ONCOLOGY

Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study

(2011) Sumihito Nobusawa et al.   NEUROPATHOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Effect of Sunitinib Combined with Ionizing Radiation on Endothelial Cells

(2010) Hai-Ping ZHANG et al.   JOURNAL OF RADIATION RESEARCH

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib

(2010) Manik Chahal et al.   NEURO-ONCOLOGY

Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004

(2010) L. Bauchet et al.   NEURO-ONCOLOGY

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines

(2009) Efstathia Giannopoulou et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

Time course of imaging changes of GBM during extended bevacizumab treatment

(2008) Suchitra Ananthnarayan et al.   JOURNAL OF NEURO-ONCOLOGY